Is BioNTech a Better Coronavirus Stock to Buy Than Its Big Partner Pfizer?

Keith Speights, The Motley Fool
·3-min read
Is BioNTech a Better Coronavirus Stock to Buy Than Its Big Partner Pfizer?
Is BioNTech a Better Coronavirus Stock to Buy Than Its Big Partner Pfizer?

In a CNBC interview last month, billionaire philanthropist Bill Gates readily identified the company that he views as the leader in the race to develop a coronavirus vaccine: Pfizer (NYSE: PFE). Pfizer could very well be the first U.S. drugmaker to seek emergency use authorization from the Food and Drug Administration for a COVID-19 vaccine. BioNTech originally developed BNT162b2, with Pfizer teaming up with the German biotech on the promising vaccine program in March 2020.